

Cytox at CTAD 2019

Without new drug therapies, the economic and healthcare cost burden of dementia - including Alzheimer's disease - is estimated to exceed \$1tn per year in the next decade (World Alzheimer's Report 2015 - www.alz.co.uk/research/WorldAlzheimerReport2015.pdf).

Cytox (www.cytoxgroup.com) has two products: *genoSCORE™* and *genoTOR™* that enable developers of Alzheimer's drugs to identify patients most at risk of developing the disease, thus improving clinical trial patient recruitment enrichment for various clinical study designs.

Identifying suitable patients for Alzheimer's clinical trials – webinar

Cytox, with its partner Thermo Fisher Scientific, hosted a webinar to showcase its products *genoSCORE™* and *genoTOR™*.

Cytox is a world-leader in developing and commercialising polygenic risk scoring (PRS) algorithms to characterise an individual's genetic risk for developing Alzheimer's disease. A polygenic risk score, also called a polygenic score, genetic risk score, hazard score or genome-wide score, provides a probability of a disease trait arising, based on multiple genetic loci and their associated disease-causing and protecting weights.

Cytox's polygenic risk score algorithm products are driven from a customised single-nucleotide polymorphism (SNP) array. This array can detect around 500,000 SNPs, providing the basis for generating a PRS and a risk evaluation of disease onset for any individual based on their genetics.



Cytox's approaches are being actively evaluated today by global pharma, biotech and sponsors of larger cohort studies as a more rigorous and cost-effective means to improve identification and stratification of at-risk subjects, for participation in clinical trials.

To view the webinar, please visit our website: www.cytoxgroup.com/newsletters

Cytox poster at CTAD:

Design of an Alzheimer's Disease Specific SNP Array for Driving Polygenic Risk Scoring Algorithms

Cytox, in collaboration with Cardiff University, The University of Birmingham, and UCL, has developed its new Alzheimer's disease single-nucleotide polymorphism (SNP) array called *variaTECT II™*.

Capable of detecting approximately 500,000 SNPs, *variaTECT II™* is believed to be the most comprehensive array for understanding the genetic profile of individuals and specifically their risk of future onset of Alzheimer's disease.

It allows for genotyping of DNA extracted from either blood or saliva and will provide all the genetic-related information from provision of an ApoE genotype to the ability to derive multiple polygenic risk scores from several algorithms.

To deliver *variaTECT II™* Cytox worked with its partner Thermo Fisher Scientific, and the array runs on the Affymetrix Axiom™ platform.

For more information on *variaTECT II™* and to see early results, please see our poster at CTAD (P78, Wednesday 4th and Thursday 5th of December).

Cytox progressing towards registration of Alzheimer's disease PRS products

variaTECT II™ - an array capable of detecting 500,000 SNPs associated with Alzheimer's disease - alongside *SNPfit™* - AI-derived algorithms and software to interpret the output of *variaTECT II™* - are the two components that power our *genoSCORE™* and *genoTOR™* products.

genoSCORE™ and *genoTOR™* enable developers of Alzheimer's drugs to identify patients most at risk of developing disease and enrich patient recruitment to clinical trials. These products are currently available for research purposes, and Cytox is preparing these for marketing approval at both the FDA and EMA.

For more information on how *genoSCORE™* and *genoTOR™* could support your Alzheimer's drug development programmes both Richard Pither (CEO) and Tony Hill (CCO) will be attending CTAD. If you would like to arrange an appointment either at the conference or another time please email CTAD2019@cytoxgroup.com.